

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Otezla (apremilast)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Detient News		Prescriber Name:		
Patient Name:		Supervising Physician	1:	
Member/Subscriber Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Group Number:		NPI:	State Lic ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name (if applicable):	
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.				
Q1. What diagnosis is this	drug heing prescribed fo	or (nick one)?		
Psoriatic arthritis	Psoriasis	Other		
T Soriatio artificis				
Q2. Please provide ICD co	de(s) for diagnosis.			
Q3. Is the prescriber a Rhe	eumatologist?			
☐Yes	□ No			
Q4. Is the prescriber a Der				
Yes	□ No			
Q5. Is the patient a new sta	art?			
Yes				
☐ No (please provide sta	rt date)			
Q6. If for psoriatic arthritis, does the member have documented spinal involvement?				
☐ Yes ☐ No				
Q7. If for psoriatic arthritis,	has the patient previous	sly failed methotrexate?		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Otezla (apremilast)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Yes	Patient Name:		Prescriber Name: Supervising Physician:		
CONTRAINDICATION to methotrexate? Yes	Yes	□ No			
LEAST ONE, or does the patient have CONTRAINDICATION(S) to OTHER DMARDs (hydroxychloroquine, sulfasalazine, leflunomide)? Yes	CONTRAINDICATION to me	thotrexate?	FAILED METHOTREXATE, does the patient have a		
Q10. Does the patient have moderate to severe plaque psoriasis affecting greater than 5% of body surface area (BSA)? Yes	LEAST ONE, or does the patient have CONTRAINDICATION(S) to OTHER DMARDs (hydroxychloroquine, sulfasalazine, leflunomide)?				
Q11. Does the patient have moderate to severe plaque psoriasis affecting crucial body areas such as hands, feet, face, or genitals? Yes	Q10. Does the patient have n		oriasis affecting greater than 5% of body surface area		
face, or genitals? Yes	☐ Yes	□ No			
Q12. If for psoriasis, has the patient failed at least TWO TOPICAL treatments [including but not limited to corticosteroids, Vitamin D analogues, Vitamin D analogue/corticosteroid combinations, Tazorac® (tazarotene)]? Yes	face, or genitals?		oriasis affecting crucial body areas such as hands, feet,		
PUVA)? Yes	Q12. If for psoriasis, has the patient failed at least TWO TOPICAL treatments [including but not limited to corticosteroids, Vitamin D analogues, Vitamin D analogue/corticosteroid combinations, Tazorac® (tazarotene)]?				
acitretin, leflunomide, sulfasalazine OR tarolimus? Yes	PUVA)?		ent have a contraindication to phototherapy (UVB or		
☐ Enbrel ☐ Humira ☐ Other (please specify)	Q14. If for psoriasis, has the patient failed, or does the patient have a contraindication to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine OR tarolimus?				
Q16. Additional Comments	☐ Enbrel ☐ Humira ☐ Other (please specify) ☐ None	atient has failed or was intoler	ant to		



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Otezla (apremilast)

Phone: 800-728-7947 Fax back to: 866-880-4532

	ges the pharmacy drug benefit for your patient. Certain requests for coverage require review questions and fax this form to the number listed above. Please note any information left
	Prescriber Name:
Patient Name:	Supervising Physician:
Prescriber Signature	Date
5 11 11 1 5 1 1 1 1 1 1	
, , , , , , , , , , , , , , , , , , , ,	signing above, I certify that applying the standard review timeframe may lee or the enrollee's ability to regain maximum function
seriously jeopardize the me of fleath of the emo	ince of the emolice 3 ability to regain maximum function
	medical necessity denial. Requesting providers may speak to the SWHP medical e an opportunity to help impact the decision on a request before coverage has bee
entity named above. The authorized recipient of this information is pro	g to the sender that is legally privileged. This information is intended only for the use of the individual or ohibited from disclosing this information to any other party. If you are not the intended recipient, you are en in reference to the contents of this document is strictly prohibited. If you have received this telecopy in if this document